TY - JOUR
T1 - Design of therapeutic vaccines
T2 - Hepatitis B as an example
AU - Kutscher, Sarah
AU - Bauer, Tanja
AU - Dembek, Claudia
AU - Sprinzl, Martin
AU - Protzer, Ulrike
PY - 2012/3
Y1 - 2012/3
N2 - Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a therapeutic vaccine shall activate the patient's immune system to fight and finally control or ideally even eliminate the virus. Whereas the success of prophylactic vaccination is based on rapid neutralization of the invading pathogen by antibodies, virus control and elimination of infected cells require T cells. Therefore, induction of a multi-specific and multifunctional T-cell response against key viral antigens is a paradigm of therapeutic vaccination - besides activation of a humoral immune response to limit virus spread. In this review, we describe options to develop a therapeutic vaccine for chronic viral infections using HBV as a promising example.
AB - Therapeutic vaccines are currently developed for chronic viral infections, such as human papillomavirus (HPV), human immunodeficiency virus (HIV), herpesvirus and hepatitis B (HBV) and C (HCV) virus infections. As an alternative to antiviral treatment or to support only partially effective therapy a therapeutic vaccine shall activate the patient's immune system to fight and finally control or ideally even eliminate the virus. Whereas the success of prophylactic vaccination is based on rapid neutralization of the invading pathogen by antibodies, virus control and elimination of infected cells require T cells. Therefore, induction of a multi-specific and multifunctional T-cell response against key viral antigens is a paradigm of therapeutic vaccination - besides activation of a humoral immune response to limit virus spread. In this review, we describe options to develop a therapeutic vaccine for chronic viral infections using HBV as a promising example.
UR - http://www.scopus.com/inward/record.url?scp=84857196807&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7915.2011.00303.x
DO - 10.1111/j.1751-7915.2011.00303.x
M3 - Article
C2 - 21958338
AN - SCOPUS:84857196807
SN - 1751-7907
VL - 5
SP - 270
EP - 282
JO - Microbial Biotechnology
JF - Microbial Biotechnology
IS - 2
ER -
